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Abstract
In this study, we took advantage of human-induced pluripotent stem cells (hiPSC) and CRISPR/Cas9 technology to
investigate the potential roles of RIPK1 in regulating hematopoiesis and macrophage differentiation, proinﬂammatory
activation, and cell death pathways. Knock-out of RIPK1 in hiPSCs demonstrated that this protein is not required for
erythro-myeloid differentiation. Using a well-established macrophage differentiation protocol, knock-out of RIPK1 did
not block the differentiation of iPSC-derived macrophages, which displayed a similar phenotype to WT hiPSC-derived
macrophages. However, knock-out of RIPK1 leads to a TNFα-dependent apoptotic death of differentiated hiPSC-
derived macrophages (iPS-MΦ) and progressive loss of iPS-MΦ production irrespective of external pro-inﬂammatory
stimuli. Live video analysis demonstrated that TLR3/4 activation of RIPK1 KO hiPSC-derived macrophages triggered
TRIF and RIPK3-dependent necroptosis irrespective of caspase-8 activation. In contrast, TLR3/4 activation of WT
macrophages-induced necroptosis only when caspases were inhibited, conﬁrming the modulating effect of RIPK1 on
RIPK3-mediated necroptosis through the FADD, Caspase-8 pathway. Activation of these inﬂammatory pathways
required RIPK3 kinase activity while RIPK1 was dispensable. However, loss of RIPK1 sensitizes macrophages to activate
RIPK3 in response to inﬂammatory stimuli, thereby exacerbating a potentially pathological inﬂammatory response.
Taken together, these results reveal that RIPK1 has an important role in regulating the potent inﬂammatory pathways
in authentic human macrophages that are poised to respond to external stimuli. Consequently, RIPK1 activity might be
a valid target in the development of novel therapies for chronic inﬂammatory diseases.
Introduction
Macrophages are key cells of the innate immune system.
They are distributed throughout the tissues of the body,
and play a key role in host defense, tissue homeostasis,
and development1. Macrophages must constantly strike a
balance between resting homeostatic functions, activated
pro-inﬂammatory functions and cell death2. Too little
activation can lead to poor pathogen clearance; too much
activation can lead to inﬂammation-mediated patholo-
gies3. Similar considerations apply to cell death; too little
cell death in the context of intracellular infection of
macrophages can lead to pathogen spread while too much
cell death can prevent the cells from performing their
effector function4. These pathways have been shown to
share ﬁnely regulated signaling platforms, in which
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receptor-interacting serine/threonine-protein kinase 1
(RIPK1) plays an essential role5–8. RIPK1 has been
reported to shift the balance between cell survival,
apoptosis, and necroptosis upon TNFα stimulation.
Initially, it was reported to act as a kinase in the formation
of the “necrosome” and triggering of RIPK3-dependent
necroptosis9,10. However, a kinase-independent role for
RIPK1 was later described, which suggests a scaffolding
role for RIPK1 to inhibit caspase-8-dependent apoptosis
and, paradoxically, necroptosis11,12. Although the dual
function of RIPK1 is best understood in the context of
TNFα signaling, a wide range of other triggers, such as
IFNαR, TLRs, viral infection, and genotoxic stress have
recently been described to trigger RIPK1 activation and
necrosome formation13. Furthermore, RIPK1 has also
been shown to play a role in the induction of pro-
inﬂammatory gene expression independently of cell
death5,6,14.
Consistent with its role in regulating inﬂammation and
cell death, the scaffolding role of RIPK1 has also been
observed to be required for normal development. For
example, the knock-out (KO) of RIPK1 in mice results in
perinatal death due to systemic inﬂammation in the
absence of infection15–17, whereas mice with kinase
inactive RIPK1 can develop normally18–20. Further char-
acterization of the RIPK1 KO mouse model showed that
the deletion of RIPK1 led to bone marrow aplasia and loss
of hematopoietic stem and progenitor cells (HSPCs)16. In
a follow-up study, two conditional RIPK1 KO mice were
generated, in which RIPK1 was deleted from adult mice or
from hematopoietic cells. For both models, the same loss
of hematopoietic cells was observed accompanied by an
increase in pro-inﬂammatory cytokines, which was
hypothesized to cause the death of HSPCs through a
RIPK3-dependent mechanism17,21. Interestingly, when
cultured ex vivo, RIPK1 KO hematopoietic stem cells
remained viable and differentiated normally, supporting
the view that the loss of hematopoietic progenitors in
RIPK1 KO mice is a consequence of a RIPK3-dependent
systemic inﬂammation. However, the poor engraftment of
RIPK1 KO progenitor cells in immunocompromised
mice, which were outcompeted by wild-type progenitors,
suggests that there may be underlying factors beyond
systemic inﬂammation21. Interestingly, recently two
independent groups identiﬁed Z-DNA-binding protein 1
(ZBP1), a RHIM-containing protein, as a critical compo-
nent in inducing MLKL-induced necroptosis, whose
activity is kept under control by RIPK1 through its RHIM
domain22,23. ZBP1 was originally identiﬁed as a pathogen
sensor and has been shown to elicit a wide array of
immune-related functions24.
Given the challenges of distinguishing the cell-intrinsic
from the systemic inﬂammatory effects of RIPK1 KO in
whole-animal models, there are advantages to using cell
differentiation and culture models, in which cellular
environments can be controlled more precisely. More-
over, the availability of human-induced pluripotent stem
cells (hiPSC) bypasses the need to study a model organism
that may differ in important ways from the human.
Accordingly, we have exploited recent advances in human
iPS-derived in vitro myelopoeisis25,26, which produces
consistently large numbers of macrop hage precursors
that can be further differentiated to microgliaor other
tissue macrophages, according to context27,28. By using
CRISPR/Cas9 technology, we knocked-out RIPK1 in
hiPSCs to study its role in human macrophage develop-
ment and function in the absence of confounding factors.
Here, we report that RIPK1 KO in human hiPSCs does
not affect undifferentiated hiPSCs or the initial differ-
entiation of hiPSC-derived macrophage precursors, but
leads to a TNFα-dependent death of fully differentiated
hiPSC-derived macrophages (iPS-MΦ) and progressive
loss of iPS-MΦ production irrespective of external pro-
inﬂammatory stimuli. In addition, RIPK1 KO iPS-MΦ
expressed higher basal levels of pro-inﬂammatory cyto-
kine transcripts than wild-type cells. The absence of
RIPK1 only increased the sensitivity of iPS-MΦ to TNFα-
induced cell death very modestly. On the other hand,
RIPK1 KO iPS-MΦ were particularly sensitive to caspase-
8 independent, TLR3 and TLR4-mediated TRIF-RIPK3-
dependent cell death and RIPK3-dependent inﬂammatory
responses.
Results
KO of RIPK1 in hiPSCs does not impair hematopoietic
differentiation
We used CRISPR/Cas9 technology to introduce frame-
shift mutations in exon 5 of RIPK1 and thereby knock out
functional expression of the gene (Supplementary Fig-
ure 1). Two RIPK1 homozygous KO hiPSC lines were
tested alongside a wild-type control clone. RIPK1 KO
hiPSC lines cells were viable, karyotypically normal and
showed no signs of differentiation (Supplementary Fig-
ure 2). RIPK1 expression was completely knocked-out at
the protein level in both RIPK1 KO hiPSC lines as shown
by western blot (Supplementary Figure 4B and C). Fur-
thermore, all hiPSC lines were capable of forming
embryoid bodies (EBs), with no signiﬁcant differences in
size and morphology between EBs from both WT and
RIPK1 KO clones (Supplementary Figure 3). RIPK1 KO
hiPSCs were differentiated to macrophages using a well-
established macrophage differentiation protocol25,26. WT
and RIPK1 KO iPS-MΦ had an indistinguishable mor-
phology and phenotype based on key macrophage surface
markers (Fig. 1a and b). Residual RIPK1 mRNA (poten-
tially encoding a truncated and non-functional polypep-
tide) was knocked-down by over 10-fold in RIPK1 KO
iPS-MΦ (Supplementary Figure 4A). However, from week
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Fig. 1 RIPK1−/− iPSCs can differentiate into macrophages but RIPK1 deﬁciency results in a progressive loss of macrophage production
over time. a Representative images of iPSC-MΦ early in differentiation, before harvest. No visual difference was observed between WT and RIPK1 KO
iPSC-MΦ at this early stage. b Flow cytometry staining of iPSC-derived macrophages for CD11b, CD16, and CD14 myeloid surface makers, showing
live cell gate on the left and histogram plots on the right, antibody staining (blue) and isotype (red). c Noncumulative production of iPSC-derived
macrophages per well over a period of 35 days of four independent experiments. Each time point represents the mean number of iPSC-derived
macrophages harvested per well of WT (n= 3), RIPK1-/- B11 (n= 3), and RIPK1-/- E3 (n= 3). Error bars denote SD. Statistical comparisons were done
using two-way ANOVA
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2 onwards, wild-type EBs generated a substantial number
of iPS-MΦ, as expected, while both RIPK1 KO clones
exhibited an initial production between week 2 and 4
post-EB formation, followed by a rapid loss of macro-
phage production (Fig. 1c). The initial production of
RIPK1 KO iPS-MΦ was variable from experiment to
experiment, and was signiﬁcantly lower than in WT
hiPSCs.
Hematopoietic progenitors are viable and differentiate
normally
The low and transient yield of iPS-MΦ from RIPK1
KO cultures, compared to WT, might have resulted
from the loss of hematopoietic progenitor cells or the
death of differentiated iPS-MΦ. To distinguish these
possibilities, we ﬁrst assessed the impact of RIPK1 KO
on the viability and lineage potential of hematopoietic
progenitor cells by performing a colony-forming assay
in semisolid media. For this purpose, hiPSC-derived
EBs were dissociated after 2 weeks of differentiation,
and equal numbers of EB-derived single cells were
plated into MethoCultTM H4344. The culture of
hematopoietic cell precursors in this medium pro-
motes the formation of erythroid progenitors (CFU-E
and BFU-E), granulocyte-macrophage progenitors
(CFU-GM, CFU-G, and CFU-M), and multi-potential
granulocyte, erythroid, macrophage, and mega-
karyocyte progenitors (CFU-GEMM) (representative
colonies are shown in Fig. 2a). The number and type of
CFUs was scored after a further 2 weeks of culture
(Fig. 2b). Both RIPK1 KO EBs and WT EBs generated
comparable numbers of erythrocyte, granulocyte, and
macrophage progenitor colonies of similar size, indi-
cating that RIPK1 is not required for erythro-myeloid
differentiation (Fig. 2b).
As the loss of macrophage production occurs after
the ﬁrst wave of production, we tested whether
hematopoietic progenitors are lost in RIPK1 KO EBs at
later time points. While there was no substantive dif-
ference in colony forming potential at 14 and 21 days of
differentiation, at day 28, the macrophage colony
forming units that were present in the WT were absent
in RIPK1 KO EBs, indicative of complete absence of
hematopoietic progenitors at this time (Supplementary
Figure 5). This indicates that the loss of RIPK1 KO iPS-
MΦ occurring from day 21 onwards precedes the loss
of hematopoietic progenitors within the EBs (Fig. 1c).
Taken together, these results indicate that early
hematopoietic progenitors, which are not yet com-
mitted to macrophage differentiation, are independent
of RIPK1, but that at later time points, during com-
mitment to the macrophage lineage, the absence of
RIPK1 affects one or more vital aspect of the cell’s
biology.
KO of RIPK1 induces progressive TNFα-dependent cell
death of macrophages
As RIPK1 is strongly linked to cell death pathways, we
investigated whether the decrease in iPS-MΦ number was
the result of reduced iPS-MΦ viability. When subjected to
the standard protocol for inducing terminal differentia-
tion (see Materials and methods) between 70% and 100%
of RIPK1 KO iPS-MΦ died within 48 h, while WT iPS-
MΦ differentiated normally and remained viable (Fig. 3a).
It was possible that the spontaneous death of RIPK1-KO
iPS-MΦ may have resulted from the dysregulation of
pathways in which RIPK1 normally transduces inﬂam-
matory signals. To test whether TNFα was involved in the
cell death of RIPK1 KO iPS-MΦ under normal culture
conditions, iPS-MΦ were subjected to the standard pro-
tocol for inducing terminal differentiation in presence or
absence of 5 µg/mL TNFα neutralizing antibody (Sup-
plementary Figure 6A and B). TNFα neutralizing antibody
treatment rescued the cell death phenotype observed
previously in RIPK1 KO iPS-MΦ (Fig. 3a). In addition,
RIPK1 KO iPS-MΦ treated with TNFα neutralizing
antibodies were still viable after 5 days in culture while
untreated KO iPS-MΦ were dead (data not shown). This
observation suggests that TNFα is involved in the pro-
gressive loss of RIPK1 KO iPS- MΦ in culture. In addi-
tion, the viability of RIPK1 KO iPS-MΦ before plating was
lower compared to WT iPS-MΦ (Fig. 3b).
KO of RIPK1 sensitizes macrophages to caspase-
independent cell death
To further investigate the cell death pathways involved in
RIPK1 KO iPSC-MΦ cell death, we stimulated iPS-MΦ
with TNFα, LPS or Poly(I:C) to trigger the three most well-
characterized inﬂammatory signaling cascades involving
RIPK1 and monitored cell viability by video microscopy
over 24 h (Fig. 3c). Unstimulated RIPK1 KO iPS-MΦ died
more rapidly than WT iPS-MΦ, an effect which was res-
cued by inhibition of caspases using zVAD-fmk, but not by
inhibition of RIPK3 using GSK-872, indicative of death by
apoptosis rather than necroptosis. TNFα produced only a
modest effect on the viability of RIPK1 KO iPS-MΦ sug-
gesting that the addition of external TNFα does not change
the kinetic of cell death of RIPK1 KO iPS-MΦ observed
previously. In contrast, LPS (at both 100 and 10 ng/mL)-
induced rapid cell death of RIPK1 KO iPS-MΦ (Fig. 3c),
which was counteracted by the RIPK3 inhibitor, GSK-872,
but not by inhibition of caspases (Fig. 3c), indicative of
necroptosis rather than apoptosis. Note that LPS-induced
moderate but variable levels of cell death in the WT
(Fig. 3c), but the remaining cells remained viable in pro-
longed culture (data not shown). As LPS is a known inducer
of TNFα in macrophages, we treated iPS-MΦ with 5 µg/mL
TNFα neutralizing antibody and stimulated them with
10 ng/mL LPS and monitored cell viability by video
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microscopy over 12 h (Supplementary Figure 6C). TNFα
neutralizing antibody failed to prevent LPS-induced cell
death. As a positive control, potency of TNFα neutralizing
antibodies was tested on J-Lat as described previously29,30.
This analysis demonstrated complete neutralization of
TNFα (Supplementary Figure 6D, E).
As LPS triggers both the MyD88 and the TRIF path-
ways31, it was not possible to conclude which pathway was
responsible for LPS-induced cell death. We therefore
stimulated the cells with poly(I:C), which triggers only the
TRIF pathway. TRIF is known to mediate formation of
secondary endosomal complexes recruiting additional
components including RIPK1 and RIPK332,33. Poly(I:C)
induced a more modest cell death response than LPS, but
one that was similarly dependent on RIPK3 rather than
caspases (Fig. 3c). Taken together, these results demon-
strate that human RIPK1 KO macrophages are highly
sensitive to TRIF-dependent, RIPK3-dependent cell death.
RIPK1 KO macrophage factories display higher basal level
of inﬂammation and respond strongly to inﬂammatory
signaling
As RIPK1 KO iPS-MΦ were highly sensitive to death
through inﬂammatory pathways, we hypothesized that the
loss of iPS-MΦ during macrophage differentiation was the
result of an elevated level of basal inﬂammation in the
cultures. In fact, this view is supported by the protective
effect of TNFα neutralizing antibodies against the death of
unstimulated RIPK1 KO iPS-MΦ. Therefore, we assessed
the levels of TNFα and IL1β mRNA in ﬁrst harvest
macrophages (day 21 post EB formation) using qPCR, and
found that they were signiﬁcantly elevated (Fig. 4a). This
indicates that even at an early stage of differentiation,
RIPK1 is normally involved in the moderation of macro-
phage activation and pro-inﬂammatory pathways in the
absence of external pro-inﬂammatory stimuli.
TLR4-mediated induction of inﬂammatory gene expression
does not require RIPK1 nor the inhibition of caspase-8
It has recently been suggested that the kinase activity of
RIPK1 promotes cell death-independent inﬂammation in
response to TLR4 stimulation and caspase inhibition;
conditions typically associated with necrosome forma-
tion14,34,35. Consequently, we analyzed mRNA levels of
TNFα and IL-1β in WT and RIPK1 KO iPS-MΦ before
and after exposure to LPS (Fig. 4b–d). In WT iPS-MΦ, as
expected, LPS induced the expression of both TNFα and
IL-1β mRNA (Fig. 4c, d), and this effect was dramatically
Fig. 2 RIPK1−/− iPSCs have normal hematopoietic progenitor numbers. a Image of the different colony types. From top to bottom, images
show a bright-ﬁeld image of representative CFU-GM, CFU-M, and CFU-E WT colonies in methylcellulose media at day 14 after methylcellulose plating.
b Day 14 EBs were dissociated and plated in methylcellulose media, colonies were scored after 14 days of colony growth. Graphs represent mean
colony count with SD of WT, RIPK1−/− B11 and RIPK1−/− E3 of three independent experiments (n= 3)
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enhanced in the presence of the caspase inhibitor, zVAD-
fmk, consistent with dependence on necrosome forma-
tion, as previously reported14. As our results on cell via-
bility, above, indicated that KO of RIPK1 may increase
necrosome formation, we hypothesized that it would also
enhance the inﬂammatory response to LPS. Strikingly, the
induction of TNFα and IL-1β transcription by LPS
in RIPK1 KO iPS-MΦmimicked that seen in WT iPS-MΦ
in the presence of the caspase inhibitor, zVAD-fmk
(Fig. 4c, d). The results indicate that RIPK1 and the loss of
Fig. 3 RIPK1−/− macrophages are prone to cell death. LPS and Poly IC induces RIPK3-dependent cell death in RIPK1−/− macrophages.
a Representative bright ﬁeld image of unstimulated WT and RIPK1−/− B11 macrophages cultured in macrophage media for 48 h. b Representative
ﬂow cytometry histograms of unstimulated WT, RIPK1−/− B11 and RIPK1−/− E3 iPSC-derived macrophages stained with PI. c iPSC-derived
macrophages were harvested and plated in an optical 96-well plate with live/dead stain and imaged for 24 h in presence or absence of LPS (10 or
100 ng/mL), Poly IC (25 µg/mL), TNFα (10 ng/mL), zVAD-fmk (10 µM) and/or GSK872 (3 µM). Percentage of live cells is plotted over time; for untreated,
TNFα and LPS 100 ng/mL each point represents the mean cell viability of three independent experiments (n= 3). For each experiment the mean
viability across three replicate wells was used. For Poly IC and LPS 10 ng/mL each point represents the mean cell viability across three replicate wells
(n= 1). Error bars denote SD. Statistical comparisons were done on the 24 h timepoint values using one-way ANOVA followed by LSD multiple
comparisons test
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Fig. 4 RIPK1−/− iPSC-derived macrophages have higher basal mRNA level of TNFα and IL-1β and higher LPS response. a Relative TNFα and
IL-1β mRNA normalized to TBP endogenous control (2−ΔCt) of freshly harvested, untreated iPSC-derived macrophages. Results from iPS-MΦ of two
independent differentiations are shown. b Representative images of iPS-MΦ cultured for 6 h in the presence or absence of LPS (100 ng/mL), zVAD-
fmk (10 µM) or GSK872 (3 µM). c, d Relative TNFα and IL-1β mRNA normalized to TBP endogenous control (2−ΔCt) of iPS-MΦ cultured for 6 h in the
presence or absence of LPS (100 ng/mL), zVAD-fmk (10 µM) or GSK872 (3 µM). Single experiment done in technical triplicate (n= 1). e TNFα release
was measured by ELISA in the supernatant of iPS-MΦ cultured for 3 h in the presence or absence of LPS (10 ng/mL), ZVad-fmk (10 µM) or GSK872
(3 µM). Each condition represents the mean TNFα release across three replicate wells. Error bars denote SD
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caspase-8 activity are dispensable for the TLR4-mediated
induction of inﬂammatory gene expression. Since necro-
some formation eventually leads to MLKL-dependent
membrane breakdown, which may elicit a proin-
ﬂammatory response in neighboring cells, we analyzed the
effect of the RIPK3 inhibitor, GSK-872, on the LPS-
response of RIPK1 KO macrophages. Under these con-
ditions, RIPK3 kinase inhibition prevented necrosome-
induced cell death (Fig. 3c), and partially prevented the
necrosome-associated upregulation of TNFα mRNA
(Fig. 4c). We conclude that kinase activity of RIPK3 plays
a signiﬁcant role in driving the necrosome-associated
inﬂammatory response. As a further step, we measured
TNFα levels in the extracellular media under conditions
minimizing cell death. To achieve this, we treated WT
and RIPK1 KO iPS-MΦ with LPS at 10 ng/mL and
extracellular TNFα was measured 3 h after treatment. Our
live video cell death analysis demonstrated that RIPK1 KO
iPS-MΦ triggered necroptosis in response to 10 ng/mL
LPS not before 5 h (Fig. 3c). In unstimulated cells,
including WT and RIPKO iPS-MΦ, no signiﬁcant TNFα
was detected in collected media (Fig. 4e). In WT iPS-MΦ,
exposure to LPS failed to signiﬁcantly induce TNFα
release to the cell media. Notably, TNFα release was
highly enhanced in LPS-treated RIPK1 KO iPS-MΦ,
which was not prevented by either caspase or RIPK3
inhibition (Fig. 4e). Overall, our results suggest that sti-
mulated RIPK1 KO iPS-MΦ, which are prone to die by
necroptosis, elicit a strong inﬂammatory response along
with enhanced TNFα release.
Discussion
Resident macrophages maintain tissue integrity by
clearing debris and dead cells, defending against patho-
gens, remodeling cells and connective tissue, and secret-
ing trophic factors for both tissue stem cells and their
progeny under physiological conditions36. However, when
their homeostatic capacity is overwhelmed, their inﬂam-
matory responses are strongly associated with the
pathogenesis of chronic diseases, including type II dia-
betes, atherosclerosis, age-related neurodegenerative dis-
eases, and chronic inﬂammatory bowel diseases37.
Consequently, an understanding of how human tissue
macrophages ﬁne-tune their inﬂammatory response to
external signals is required for rational approaches to
treating these increasingly prevalent diseases, without
compromising their vital tissue defence and homeostatic
functions. Studies, largely on human cancer cell lines
in vitro and in transgenic mouse models, have revealed a
complex web of regulatory pathways that integrate the
responses of cells to inﬂammatory cytokines, such as TNF
and to pathogen-associated molecular patterns (PAMPs)
such as LPS7,12,16,17,21. In these reports, RIPK1 is found to
play an important role; sometimes promoting and
sometimes inhibiting the effector functions of caspase-8
and RIPK3, depending on circumstance
In order to investigate the relative contribution of
RIPK1 to inﬂammatory and cell death pathways in normal
human macrophage development and function, in this
study we have generated KO of RIPK1 in human iPS cells,
and used a well-established model of iPS-MΦ differ-
entiation. We show that RIPK1 is not required for
erythro-myeloid differentiation. However, soon after the
initiation of differentiation, in the absence of RIPK1,
hematopoietic progenitors are lost, and unstimulated
differentiated iPS-MΦ switch to a primed, proin-
ﬂammatory phenotype, and then tend to die. As myeloid
precursors become committed to the macrophage differ-
entiation pathway, they acquire potent, lineage-speciﬁc
response pathways that need to be held under control in
order to prevent self-inﬂicted damage in the absence of an
appropriate external stimulus. Our results suggest that
RIPK1 might be critical in maintaining tonic control of
macrophage activation pathways, allowing the cells to
respond rapidly to stimuli from an active but sub-critical
level. In this regard it resembles the phenomenon of tonic
signaling in lymphocytes38. Supporting this view, we
provide evidence that in the absence of RIPK1, unstimu-
lated differentiated iPS-MΦ die by intrinsic TNFα-
dependent apoptosis.
Our results show that activation of RIPK1 KO iPS-MΦ
by TLR ligands triggers a robust induction of TNF mRNA
transcription and commits them to die by necroptosis.
The necroptotic nature of the TLR4-induced cell death in
RIPK1 KO macrophages was conﬁrmed by using GSK-
872, a speciﬁc RIPK3 inhibitor, that prevented cell death.
TLR3 stimulation by poly(I:C) likewise resulted in RIPK3-
dependent, caspase-independent cell death, conﬁrming
the ability of TRIF to trigger RIPK3 activation without the
need for RIPK1 recruitment.
The ﬁrst evidence demonstrating a scaffolding role of
RIPK1 in preventing necroptosis came from studies using
transgenic mice showing that loss of RIPK3 protects
RIPK1/caspase-8 KO mice, which die shortly after
birth16,39,40. Further studies have shown the ability of
RIPK1 to prevent necroptosis in murine cells11,12. Our
study demonstrates that RIPK1 plays a pro-survival role
against an autocrine apoptotic TNFα tonic signal in
unstimulated macrophages and against necroptosis in
TLR-stimulated human macrophages. In some settings, it
has been established that necroptosis requires RIPK1-
kinase activity41,42. Our data are consistent with the view
that this kinase activity counter-balances the scaffolding
role of RIPK1 in preventing necroptosis in activated
tissue-resident macrophages.
Our experimental system, using human hiPSCs lacking
RIPK1, has enabled us to ascertain the potentially diver-
gent roles of RIPK1 in regulating cell death and
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inﬂammation, respectively (Fig. 5). As a ﬁrst step, we
analyzed the mRNA levels of two key proinﬂammatory
cytokines orchestrating inﬂammation, TNFα and IL-1β, in
unstimulated human WT and RIPK1 KO macrophages7.
Strikingly, the basal transcription of both genes was
strongly elevated in macrophages lacking RIPK1, con-
sistent with a chronic primed proinﬂammatory pheno-
type. It is well established that exposure of primed
macrophages to DAMPs make them extremely reactive,
secreting large amounts of proinﬂammatory molecules43.
Chronic proinﬂammatory activation of RIPK1 KO human
macrophages could result from a vicious cycle of
necroptosis, DAMP release and priming of bystander
cells. However, the necrosome may elicit an intrinsic
MLKL-independent proinﬂamamatory response through
engagement of the NLRP3 inﬂammasome to activate
IL1β44. RIPK3 has been also shown to facilitate the pro-
duction of cytokines independent on their role in
necroptosis in response to combined IAP deletion, inhi-
bition by Smac mimetic treatment or even XIAP dele-
tion45,46. More recently, critical roles for the kinase
activities of RIPK1 and RIPK3 in LPS-induced expression
of inﬂammatory cytokines in bone marrow-derived
macrophages have been revealed14,35. Consequently, there
is strong evidence supporting the view that necroptosis-
driven inﬂammatory response does not exclusively rely on
DAMP release.
Accordingly, we sought to analyze the role of RIPK1 in
regulating inﬂammation under conditions of necrosome
formation. In conﬁrmation of earlier ﬁndings in WT cells,
caspase inhibition increased TNFα and IL-1β mRNA
levels in LPS-stimulated iPS-MΦ, a process that has been
suggested to be regulated by RIPK1 kinase activity14.
However, if RIPK1 were a requirement for the
necrosome-dependent inﬂammatory pathways, inﬂam-
matory cytokine expression should be attenuated in LPS-
treated, caspase-inhibited RIPK1 KO compared to WT
iPS-MΦ, whereas they showed comparable levels. Intri-
guingly, RIPK3 kinase inhibition partially prevented the
upregulation of TNF transcription by LPS in RIPK1 KO
macrophages. We conclude that RIPK1 is dispensable,
while RIPK3 is indispensable, for the necrosome-depen-
dent, cell-intrinsic inﬂammatory response.
Our ﬁndings suggest that RIPK1 is not only dispensable
for necrosome-dependent inﬂammatory pathways in
human macrophages, but plays a key role in maintaining
TNF
TNFR1
TRADD
RIPK1
Cas-8
apoptosis
zVAD-fmk
RIPK3
MLKL
necroptosis
GSK’872
NFkB
Survival
Pro-inﬂamm
IFN LPSp(I:C)
TLR4
TRIFJak-STAT
TLR3IFNAR
RIPK1
Complex 
II
Complex 
I necrosome
RIPK1
DAMPSTNF
TNF
Pro-inﬂamm Inﬂammasome
IL1-β
Pro-IL1-β
TNF
IL1-β
Fig. 5 Scheme illustrating potential mechanisms by which RIPK1 regulates inﬂammatory and cell death pathways in human macrophages.
Main receptors engaged to RIPK1 signaling are TNFR1, TLR3 and TLR4 (via TRIF pathway) and interferon receptors. TNFR stimulation recruits TRADD
and RIPK1 thus leading to the formation of membrane bound complex I and subsequent NF-kB activation. At this step, NF-kB triggers transcription of
proinﬂammatory (i.e. TNF and pro-IL1β) and survival factors (i.e. cFLIP; not shown). Deubiquitination of Complex I induces the formation of Complex
II, which may induce apoptosis through activation of caspase-8 (Cas-8). However, under conditions of caspase-8 inhibition, which can be induced by
the pan-caspase inhibitor zVAD-fmk (zVAD), a cell death-related platform called necrosome is formed. Necrosome formation is also associated to
stimulation of TLR3, TLR4, and IFNAR through interaction and further oligomerization of RIPK1 and RIPK3, a process also requiring reduced caspase-8
activity. Necrosome formation induces the phosphorylation of MLKL, which then disrupts membrane integrity to cause necroptosis. This process can
be prevented by kinase inhibitors of RIPK3, like GSK´872. Necroptosis is accompanied by concomitant release of danger-associated molecular patterns
(DAMPS), which may amplify the inﬂammatory response through stimulation of pattern recognition receptors, including the ones depicted in the
ﬁgure. In absence of RIPK1, necrosome formation (RIPK3 oligomerization) is achieved without the need of caspase-8 inhibition. Necrosome formation
is inherently associated to strong inﬂammatory response, which can be partially prevented by RIPK3 kinase inhibition
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them in a tonic state that prevents inappropriate, cell
intrinsic TNFα-dependent apoptosis in the absence of
appropriate external stimuli, so that these very potent
defences are not deployed prematurely, resulting in self-
harm. Elucidating these RIPK1-dependent regulatory
pathways may open new therapeutic strategies against
chronic pathological inﬂammatory diseases in which
proinﬂammatory priming of macrophages is a distinctive
feature.
Materials and methods
hiPSC culture
The previously characterized human iPSC line OX1-61
(alternative name SFC841-03-01)47, reprogrammed using
non-integrating Cytotune Sendai virus reprogramming kit
(Invitrogen), was the target line for all gene editing in this
study. The line was originally derived from a healthy
donor recruited through the Oxford Parkinson’s Disease
Centre having given signed informed consent, which
included derivation of hiPSC lines from skin biopsies
(Ethics Committee that speciﬁcally approved this part of
the study, National Health Service, Health Research
Authority, NRES Committee South Central, Berkshire,
UK, REC 10/H0505/71). All experiments were performed
in accordance with UK guidelines and regulations and as
set out in the REC. The line has been deposited in the
European Bank for iPS cells, EBiSC, https://cells.ebisc.org/
STBCi044-A. Low-passage, QC’ed stocks of iPSCs were
thawed and plated on hESC qualiﬁed matrigel-coated
plates (Scientiﬁc Laboratory Supplies 354277) and cul-
tured in mTeSRTM1 (StemcellTM technologies) media,
passaging routinely with 0.5 mM EDTA48, or when
necessary with TrypLE (Thermoﬁsher) and supplement-
ing the replating medium with 10 µmol/L Rho-kinase
inhibitor Y-27632 (Abcam).
CRISPR-Cas9 gene editing
The CRISPR-Cas9 vectors used in this study were based
on the dual Cas9- and guide RNA (gRNA)-, puromycin-
resistance gene-expressing, pSpCas9n(BB)-2A-Puro
(pX462) vector49 (a gift from Feng Zhang: Addgene
plasmid #48141). Vectors were cloned as previously
described49 using oligonucleotides 5′-CACCGAGTTTG
CTCCACATCTTAA-3′ and 5′-AAACTTAAGATGTGG
AGCAAACTC-3′ with pX462 to create pX462-gRIPK1t;
oligonucleotides. Transfection of the plasmids was per-
formed by electroporation on 2 × 106 feeder-free iPSCs in
single-cell suspension (Neon® transfection system, Invi-
trogen), as previously described50. Cells were subse-
quently selected for puromycin resistance (0.4 µg/mL; MP
Biomedicals) for 48 h, after which the surviving cells were
plated on mitotically inactivated mouse embryonic
ﬁbroblast feeder cells (MEFs)51,52 in hESC medium
(KO-DMEM, 2mmol/L L-glutamine, 100 mmol/L non-
essential amino acids, 20% serum replacement, and 8 ng/
mL basic ﬁbroblastic growth factor (FGF2)), supple-
mented with 10 µmol/L Y-27632 on the day of passage.
The single cell colonies were picked manually onto
Matrigel-coated 96-well plates in mTeSRTM1 and
expanded for 7 days. Individual clones were then pre-
screened by high-resolution melt analysis (HRM) on a
StepOnePlusTM Real-Time PCR System (ThermoFisher),
using the primers 5′-CAAACAATCCC
AGTGGCTCAA-3′ and 5′-GTAGTAGAGGGTGCCG
CCATT-3′. Potential KO clones were then sequenced and
analyzed for insertions and/or deletions. The selected
clones were subsequently expanded and characterized as
previously described47 to conﬁrm expression of plur-
ipotency proteins TRA-1-60 and NANOG, and SNP
analysis was conducted to conﬁrm normal karyotype and
for cell line tracking, using Illumina OmniExpress24 array
(700,000 markers).
Macrophage differentiation from iPSCs
EBs were generated as previously described25,26, with
minor modiﬁcations as follows. iPSC in single cell sus-
pension were centrifuged in 96-well ultra-low adherence
plates (Costar 7007) at 1.25 × 105 cells/mL in EB media
(mTeSRTM1 (StemcellTM technologies), 50 ng/mL
BMP-4 (GIBCO PHC9534), 20 ng/mL SCF (Miltenyi
Biotec Ltd), 50 ng/mL VEGF (GIBCO-PHC9394)) sup-
plemented with 10 µmol/L Y-27632 on the day of EB
formation. Cells were fed with EB media ± 50 µL for
4 days. After 4 days, the differentiated EBs were trans-
ferred into a six-well tissue culture plate at a ratio of 8
EBs/well in monocyte differentiation media (X-VIVOTM-
15 (Lonza), 100 ng/mL M-CSF (Invitrogen), 25 ng/mL
IL-3 (R&D), 2 mM glutamax (Invitrogen), and 0.055 mM
2-mercaptoethanol (Invitrogen). From weeks 3 to 5, the
non-adherent iPS-MΦ produced were harvested every
week and counted using NC-3000 Viability and Cell
Count Assays (Chemometec) according to manufacturer’s
instructions.
iPS-MΦ terminal differentiation
For terminal differentiation of iPS-MΦ, freshly har-
vested non-adherent iPS-MΦ were plated in macrophage
differentiation media (X-VIVO™-15 (Lonza), supple-
mented with 100 ng/mL M-CSF (Invitrogen), 2 mM glu-
tamax (Invitrogen), 100 U/mL penicillin, and 100mg/μL
streptomycin (Invitrogen), and cultured for an additional
week.
Embryoid body dissociation and colony forming assay
Day 14 EBs were dissociated by treatment with Accu-
max™ Solution (Sigma) at 37 °C followed by mechanical
dissociation (as described previously27). An additional
10-min incubation step was added for the day 21 and day
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28 EBs. The resulting cell suspension was ﬁltered and 3 ×
104 cells plated in MethoCultTMH4344 (STEMCELL
technologies) semisolid media. On day 14 post-dissocia-
tion, colonies were classiﬁed and counted based on their
morphology.
Quantiﬁcation of cell death by live microscopy
hiPS-MΦ were resuspended in macrophage media
supplemented with 20 µL/mL ReadyProbes Cell Viability
Kit, Blue/Green (ThermoFisher-R37609). hiPSC-MΦ
were then plated at 3 × 104 cells per well in a clear bot-
tom 96-well plate and treated with: 10 ng/mL TNFα
(Peprotech) 10 or 100 ng/mL LPS (Sigma), 25 µg/mL poly
(I:C) (Sigma), 10 µM zVAD-fmk (BD PharmingenTM-
550377) and/or 3 µM GSK872 (BioVision-2673-5). Cells
were imaged every hour for 24 h in an EVOS automated
microscope (Thermoﬁsher) in a humidiﬁed 37 C, 5% CO2
incubation chamber. Number of green (dead) and live
(blue) nuclei was calculated using imageJ. Percentage of
viable cells over time was deﬁned as the ratio between live
and dead cells.
Flow cytometry staining and antibodies
Harvested macrophages were pelleted at 400×g for 5
min and washed once with PBS before being resuspended
in 100 μL of FACS buffer (PBS+ 10 μg/mL human serum
IgG+ 1% fetal bovine serum (FBS)). Cells were stained in
FACS buffer+ antibody (dilution 1:100) for 45min at 4 °C
or propidium iodide (PI) stained at 1 µg/mL for 15 min at
RT. PI Stained cells were washed PBS and analyzed using
a FACSCalibur ﬂow cytometer (BD) without ﬁxation.
Antibody stained cells where washed using PBS and
resuspended in 2% formaldehyde before being analyzed
using a FACSCalibur ﬂow cytometer (BD). The following
antibodies have been used in this study: α-CD14-FITC
(antibody (MEM-15; Immunotools), Mouse IgG1-FITC
isotype (PPV-06; ImmunoTools), α-CD16-APC (LNK16;
Immunotools), Mouse IgG1-APC isotype (PPV-06;
ImmunoTools), α-CD11b-APC (ICRF44; BioLegend),
Mouse IgG1-APC Isotype (MOPC-21; BioLegend). iPSC
lines were stained for TRA-1-60 (1.5 mg/mL; α-TRA-1-
60-AlexaFluor R488; Biolegend) and NANOG
(0.3 mg/mL; α-NANOG-AlexaFluor R647; Cell Signaling
Technologies) as previously described47.
RNA extraction, reverse transcription and quantitative
polymerase chain reaction
Freshly harvested iPSC-MΦ were either pelleted and
lysed directly or plated at 7 × 105 cells/well in a 12-well in
macrophage media and cultured for 6 h in presence or
absence of 100 ng/mL LPS, 10 µM zVAD-fmk and/or
3 µM GSK before being lysed in the plate. Cells were lysed
using RLT buffer (QIAGEN) supplemented with 10 µL
β-ME. RNA extraction was performed using the RNeasy®
kit (QIAGEN) according to manufacturer’s protocol.
Potential DNA contamination was removed by adding a
step of Ambion® TURBO DNA-free® according to man-
ufacturer’s protocol (Life technologies). Reverse tran-
scription was performed using the High capacity RNA-to-
cDNA kit (Applied Biosystems™) according to manu-
facturer’s protocol. qPCR was performed using Brilliant
III SYBR® (Agilent) on the Applied Biosystems® StepO-
nePlus™ Real-Time PCR System. The Following primers
were used:
Target Forward primer (5′–3′) Reverse primer (5′–3′)
TATABox
protein
GAACCACGGCACTGATTTTC CCCCACCATGTTCTGAATCT
RIPK1 TTACATGGAAAAGGCGTGATACA AGGTCTGCGATCTTAATGTGGA
TNFα TGTTGTAGCAAACCCTCAAGC TATCTCTCAGCTCCACGCCA
IL1-β AAAGCTTGGTGATGTCTGGTC GGACATGGAGAACACCACTTG
Western blot
Four-day old EBs or undifferentiated iPSCs were lysed
in RIPA buffer (Sigma) for 30min on ice. Lysates were
centrifuged at 17,000×g for 15 min at 4 °C and clariﬁed
supernatant protein concentration was quantiﬁed using
Pierce® BCA protein assay kit (Thermo Fisher Scientiﬁc)
and 25 μg of protein was denatured in NuPAGE LDS
Sample Buffer and NuPAGE™ Sample Reducing Agent by
heating to 70 °C for 5 min. Proteins were run on a
NuPAGE 4–12% Bis–Tris Gel (Life technologies), and
transferred on a nitrocellulose membrane (Amersham
Protran). The membrane was stained overnight at 4 °C in
PBS+ 5% BSA+ 0.05% Tween 20 with primary anti-
bodies: 0.5 µg/mL of mouse monoclonal RIPK1 antibody
(MAB3585-R&D) and 0.1 µg/mL of polyclonal rabbit
Anti-α-Actin-1 antibody (A00885-GenScript). Secondary
antibody staining was done using Goat anti-Mouse IgG
(H+ L) Secondary Antibody, DyLight 800 4X PEG and
Goat anti-Rabbit IgG (H+ L) Secondary Antibody,
DyLight 680 at 1:10,000 for 2 h at RT. Blot was scanned
using a LI-COR Odyssey scanner.
TNFα ELISA
Freshly harvested iPS-MΦ were plated at 3 × 104 cells
per well in a 96-well plate in 100 µL macrophage media
and treated with 10 ng/mL LPS (Sigma), 10 µM zVAD-
fmk (BD PharmingenTM-550377) and/or 3 µM GSK872
(BioVision-2673-5). Supernatant was collected after 3 h
and stored at −80 °C before ELISA. Human TNF alpha
Uncoated ELISA (Invitrogen-88-7346-22) was performed
according to manufacturer’s instructions, media samples
were diluted 1:50 and 100 µL was used.
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TNFα blocking experiments
For quantiﬁcation of TNFα involvement in the cell
death of RIPK1 KO iPS-MΦ under normal culture con-
ditions, iPS-MΦ were plated at 3 × 104 cells per 96-well
and subjected to the standard protocol for inducing
terminal differentiation in presence or absence of 5 µg/mL
TNFα neutralizing antibody. 48 h after plating cells,
images were taken and total number of cells per ﬁeld was
quantiﬁed manually on ImageJ. For live quantiﬁcation of
cell death, iPS-MΦ were harvested and plated in a four
chamber ibidi µ-Dish 35mm dish in MΦ-media con-
taining 10 µg/mL PI (Invitrogen-P3566) and preincubated
for 2 h with 5 µg/mL TNFα neutralizing antibody (R&D-
MAB2101R). iPS-MΦ were imaged for 12 h, one image
per 15min in presence or absence of LPS (10 ng/mL) in a
Nikon BioStation iMq. Five ﬁelds were acquired per
condition. Total number of starting cells per ﬁeld were
counted manually on imageJ and number of PI positive
nuclei were counted automatically for each timepoint
using an imageJ macro. For J.Lat 10.6 cells reactivation,
105 J.Lat 10.6 were cultured in RPMI+ 10% FBS in a
round 96-well plate and preincubated for 2 h with or
without 5 µg/mL TNFα neutralizing antibody (R&D-
MAB2101R) after which they were stimulated with
increasing concentrations of recombinant human TNFα
(Sigma-H8916). After 24 h, cells were ﬁxed for 10 min in
4% paraformaldehyde and percentage of GFP+ cells was
quantiﬁed by ﬂow cytometry on a BD FACSCanto II.
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